, 2012), three Connect2 projects were selected for detailed study according to criteria including KU 57788 implementation timetable, likelihood of measurable population impact and heterogeneity of overall mix of sites. These study sites were: Cardiff, where a traffic-free bridge was built over Cardiff Bay; Kenilworth, where a traffic-free bridge was built over a busy trunk road; and Southampton, where an informal riverside footpath was turned into a boardwalk (Ogilvie et al., 2012). None of these projects had been implemented during the baseline survey in April 2010. At one-year follow-up, most feeder

routes had been upgraded and the core projects had opened in Southampton and Cardiff in July 2010. At two-year follow-up, almost all feeder routes were complete and the core Kenilworth project had opened in September 2011. Fig. 1 illustrates the traffic-free bridge built in Cardiff (the ‘core’ project in this setting) plus the feeder routes implemented in 2010 and 2011 (the ‘greater’ network). The baseline survey used the edited electoral register to select 22,500 adults living within 5 km road network distance of the core Connect2 projects (Ogilvie et al., 2012). In April 2010 potential participants were posted

a survey pack, which 3516 individuals returned. These 3516 individuals were posted follow-up surveys in April 2011 and 2012; 1885 responded in 2011 and 1548 in 2012. After excluding individuals who had moved house, the one-year follow-up study LGK-974 price population comprised 1849 participants (53% retention rate, 8% of the population originally approached) and the two-year study population comprised 1510 (43% retention, 7% of the original population). The University of Southampton Research Ethics Committee granted ethical approval (CEE200809-15). Table 1 presents the baseline characteristics examined as predictors of Connect2 use. Past-week walking and cycling for transport were measured using a seven-day recall

instrument (Goodman et al., 2012 and Ogilvie et al., 2012) while past-week recreational walking and cycling were measured by adapting the short form of the International Physical Activity Questionnaire (Craig et al., 2003). Most other predictors were similarly self-reported, including height and Thymidine kinase weight from which we calculated body mass index (categorised as normal/overweight/obese). The only exception was the distance from the participant’s home to the nearest access point to a completed section of the greater Connect2 infrastructure (calculated separately in 2011 and 2012 to reflect ongoing upgrades: Fig. 1). This was calculated in ArcGIS 9 using the Ordnance Survey’s Integrated Transport Network and Urban Path layers, which include the road network plus traffic-free or informal paths. For ease of interpretation, we reverse coded distance from the intervention to generate a measure of proximity – i.e. treating those living within 1 km as having a higher proximity than those living over 4 km away (Table 1).

The associations observed for the magnitude of the change in perceptions (additional file C) were

generally similar to those presented in Table 4. Results of these models were similar, or at least not Protease Inhibitor Library order contradictory, to those using continuous outcome measures (Table 5). Those who reported more convenient public transport (OR: 3.31, 95% CI: 1.27, 8.63) or that it was safer to cycle (OR: 3.70, 95% CI: 1.44, 9.50) over time were more likely to take up alternatives to the car. Commuters who reported that routes had become less pleasant for walking or more dangerous for cycling, or that roads had become more difficult to cross, were more likely to report an increase in car trips, a decrease in time spent walking or both. Increases in perceived convenience of public transport and safety UMI-77 for cycling were associated with uptake of alternatives to the car. The findings from the analyses of uptake, and of changes in weekly duration of walking and cycling, were complementary but not identical. The analyses of uptake compared participants who took up any walking or cycling with those who never reported the behaviours and were therefore restricted to a subsample of participants, whereas continuous measures of changes in time spent walking and cycling were computed

for all participants. Whilst those who reported less supportive conditions for walking and cycling over time reported an increase in car trips and (to a lesser extent) a decrease in time spent walking, these associations were not mirrored by significant changes in the opposite direction associated with positive environmental changes. However, the directions of the effects were consistent in that the point estimates of the regression coefficients associated

with positive and negative environmental exposures were generally of opposite signs. Consistent with the observation that environmental changes may be ‘necessary but not sufficient’ to promote physical activity ( Giles-Corti and Donovan, 2002), it may be necessary to address both the barriers to and facilitators of physical activity behaviours Calpain to achieve sustained behaviour change. However, the lack of consistent statistical significance across all analyses highlights the need for rigorous evaluation to confirm the effects of environmental interventions in practice. The associations observed between changes in environmental perceptions and changes in car use were not simply the inverse of the associations with active travel. This may be partly explained by the fact that these behaviours are not mutually exclusive: in this study, 31% of car users reported some walking and cycling in combination with car use at t1 (Panter et al., 2013b). The different patterns of associations suggest that some environmental interventions (e.g.

RF captured all CLSM images and prepared them for publication. DX, BM, RP and JGC conceived, co-ordinated, designed and procured the funding for the study. All authors have read and approved the final article. This work was supported by the Medical

Research Council (grant no. G0801955). The authors would like to thank Dr. Katrina Davidson, Dr. Clair Lyle and Dr. Johann Partridge of XstalBio Ltd. for their invaluable technical advice and support throughout this study. We would also like to thank Dr. Fatme Mawas and David Eastwood (NIBSC) for advice on flow cytometry and Mrs. Margaret Mullin (University of Glasgow) for her support with SEM. Conflicts of interest: BM is a shareholder in XstalBio Ltd. which is a private company commercially developing CaP-PCMCs. “
“Bluetongue virus is the type species of 17-AAG datasheet genus Orbivirus, family Reoviridae [1] and [2]. Bluetongue viruses (BTV) are transmitted by adult Culicoides midges, causing ‘bluetongue’ (BT), a non-contagious but economically important disease of ruminants (sheep, cattle and some species of deer) [3] and [4]. Currently 26 BTV serotypes have been identified, 10 of which (BTV-1, 2, 4, 6, 8,

9, 11, 14, 16 and 25) have been detected in Europe since 1998 [5], [6] and [7]. It is estimated that over one million sheep have died during repeated BT incursions into the Mediterranean AZD2281 basin between 1998 and 2005 [5]. An outbreak caused by BTV-8 that started in the Netherlands during 2006, subsequently spread across most of Europe, causing high levels of of mortality in sheep (15–32%, reaching ∼50% is some areas), as well as significant clinical signs but low mortality (<1%) in cattle [8], [9], [10], [11], [12] and [13]. However, inactivated-virus vaccines were used successfully, leading to the rapid eradication of BTV-8 from the region.

These inactivated vaccines, which were made available for serotypes 1, 2, 4 and 8 of BTV are thought to work primarily through generation of a protective serotype-specific neutralising-antibody response targeting the VP2 antigen [2], [14], [15], [16], [17], [18], [19], [20] and [21]. The BTV particle is made of seven structural proteins (VP1–VP7) [2], [22] and [23]. VP2 represents a primary target for neutralising antibodies [1], [2], [16] and [17] and determines virus serotype [24]. VP2 shows 22.4–73% aa sequence variation between BTV serotypes [24]. VP5 of BTV, the second most variable BTV protein (aa identity of 41–79% between BTV serotypes [25] and [26]) enhances neutralising antibody response to VP2 [1], [2], [14] and [27]. Selected structural-proteins of BTV-4, including two domains of VP2 (aa 63–471 and 555–956), VP5 (from which a coiled-coil sequence [amino acids 1–100] was deleted to improve solubility) and full-length VP7, were expressed in bacteria as soluble fusion-proteins with glutathione S-transferase (GST).

This analysis would be useful in terms of baseline data to facilitate further surveillance. This study was funded by a research grant MDV3100 from Shantha Biotechnics Limited. All the authors except Prasad R., Saluja T. and Dhingra M.S. were the Investigators/Co-Investigators

of the study at their respective study sites. All the Investigators declared that they had no financial interests in the manufacturer but received research grant to undertake the study. Prasad R., Saluja T. and Dhingra M.S. are employed by Shantha Biotechnics Limited and were involved in planning, analyzing and interpreting the study. We are grateful to the study staff and both the Institutes for being part of this retrospective study. “
“Rotavirus diarrhea contributes to an estimated 450,000 annual childhood deaths globally and is the most important cause of diarrheal mortality

in the developing world [1]. Effective vaccines to prevent rotavirus diarrhea are licensed and available in several countries and offer a potent public health intervention in high mortality developing country settings [2]. Since 1999, when a tetravalent rhesus reassortant rotavirus vaccine (RotaShield, Wyeth Laboratories, Marietta, Pennsylvania) was linked to a 1 in 10,000 excess risk of intussusception following rotavirus immunization [3] and [4], concerns regarding intussusception Oxalosuccinic acid have been associated with rotavirus vaccination.

Currently licensed vaccines from Glaxo Smith ABT-263 research buy Kline and Merck were evaluated in large safety studies that did not demonstrate increased risk of similar magnitude [5] and [6]. However postlicensure studies with both these vaccines, have identified a safety signal with 1–5 excess cases of intussusceptions in 100,000 immunized infants in different parts of the world [7], [8], [9], [10] and [11]. While the risk benefit ratio of these vaccines remains overwhelmingly in favor of the vaccine [9] and [12], these concerns are likely to be key considerations in decision-making around introduction in a National Immunization Program (NIP). When a new vaccine, especially one with a well-publicised, albeit rare, adverse event is introduced into a NIP, heightened awareness is likely to result in early reporting of events including self-limiting events which would not earlier have been documented. Interpreting post-introduction surveillance data of adverse events requires careful planning and an understanding of underlying event rates [13]. Intussusception, the commonest cause of acute intestinal obstruction in infants, involves the invagination of a bowel segment into another, and may occur in different segments of the small and large intestines.

2 and 7 The (R)-configuration was established for all of these compounds. 2 and 7 Therefore, the anti-inflammatory activity of the naturally occurring (R)-5 enantiomer is known, but the activity of the (S)-5 enantiomer and racemate is unknown. A study of the anti-inflammatory activity of both the enantiomers could provide an answer to the

question whether nature truly provides the best therapeutic options. All reagents were obtained from Aldrich chemicals suppliers and solvents were obtained from a commercial supplier and used without further purification. All reaction mixtures were magnetically stirred selleck products and monitored by TLC using Kieselgel 60 F254 obtained from Merck (Darmstadt, Germany). 1H and 13C NMR spectra were recorded on a Bruker AVANCE

III at 400 MHz with CDCl3 as internal reference. The value for chemical shift (δ) is given in ppm and coupling constants (J) in Hertz (Hz). Melting points were recorded with a Mel-Temp melting point apparatus in open capillaries and are uncorrected. Optical rotations were measured at room temperature in chloroform using a Perkin Elmer Polarimeter-Model 341. High-resolution mass spectroscopy (HRMS) data was recorded on a Waters Micromass Q-Tof Micro mass spectrometer with a lock Selleckchem MEK inhibitor spray source. Synthetic procedure, 1H and 13C NMR data were previously reported8; mass m/z = 227 (M + 1)+. Rf = 0.24 on silicagel with ethyl acetate/hexane (30:70). Synthetic procedure, 1H and 13C NMR data were previously reported8; mass m/z = 209 (M + 1)+. Rf = 0.54 on silicagel with ethyl acetate/hexane (30:70). Synthetic procedure, 1H and 13C NMR data were previously reported.8 HRMS calcd for C18H17O4 [M + H]+ 297.1049, found 297.1121; Rf = 0.58 on silicagel with ethyl acetate/hexane (30:70).

To a solution of 5,7-dimethoxy-3-(4′-hydroxybenzylidene)-4-chromanone (1.0 g, 3.2 mmol) in a mixture of anhydrous MeOH/THF (1:1, 20 ml) at a temperature of 0 °C, Pd/c (0.4 g, 3.8 mmol) was added portion wise. H2 gas was passed through the stirred mixture at room temperature for 0.5 h after which it was filtered through celite and concentrated under reduced pressure. The residue obtained after evaporation of the solvent was chromatographed Thalidomide over a silicagel column using mixture of ethyl acetate/hexane (20:80) as eluent to produce the homoisoflavanone (R,S)-5. Yield 68%; Rf = 0.43 (20:80 ethyl acetate/hexane); mp 174–176 °C; light yellow powder; 1H NMR (400 MHz, CDCl3) δ: 2.65 (1H, dd, J = 10.4, 13.5 Hz, H-9a), 2.68–2.70 (1H, m, H-3), 3.15 (1H, dd, J = 4.1, 13.4 Hz, H-9b), 3.81 (3H, s, Ar-OCH3-7), 3.86 (3H, s, Ar–OCH3-5), 4.12 (1H, dd, J = 4.2, 7.0 Hz, H-2a), 4.27 (1H, dd, J = 3.9, 11.2 Hz, H-2b), 6.06 (1H, s, H-8), 6.07 (1H, s, H-6), 6.80 (2H, d, J = 8.4 Hz, H-2′,6′), 7.07 (2H, d, J = 8.4 Hz, H-3′,5′); 13C NMR (100 MHz, CDCl3) 32.1 (CH2, C-9), 48.6 (CH, C-3), 55.0 (OCH3, C-7), 55.8 (OCH3, C-5), 68.8 (CH2, C-2), 92.8 (CH, C-8), 93.2 (CH, C-6), 130.2 (CH, C-2′,6′), 105.4 (C, C-4a), 115.

Although approximately 30% to 70% of people with neck pain improve spontaneously over time,1, 15 and 16 neck pain can be a persistent or a recurrent disorder.1 and 17 Thus, it is important to investigate if MDT provides additional benefit in comparison to natural resolution of neck pain and other therapeutic approaches. The approach of MDT emphasises patient education throughout the treatment so that patients can obtain

skills to both manage their current episode of neck pain and prevent or self-treat future recurrences independently. Therefore, it is also important to investigate long-term effects in addition to short-term effects. A systematic review with meta-analysis of randomised selleck screening library trials is required to synthesise the evidence about the effectiveness of MDT on pain intensity and disability in the short, intermediate and long term in comparison to wait-and-see control and to other therapeutic approaches. In 2004, a systematic selleck inhibitor review was conducted to try to synthesise randomised trials of MDT for spinal pain compared to other therapeutic

approaches.18 However, only one randomised trial of MDT for neck pain was included in that review, so findings were inconclusive. In 2006, the MDT textbook for neck pain, including whiplash-associated disorders,14 was updated considerably.19 Research on MDT has been increasing over the past decade. Therefore, this systematic review was deemed necessary to estimate the effectiveness of MDT on neck pain and disability from unbiased evidence. The research questions were: 1. In people with neck pain, does MDT reduce pain and disability more than a wait-and-see control? A systematic search was performed in PubMed, SCOPUS, EMBASE, CINAHL, Physiotherapy Evidence Database (PEDro) and the Cochrane library, from inception to May 2013. The refined key search terms included: McKenzie therapy, McKenzie method, McKenzie approach, McKenzie

treatment or mechanical diagnosis, and neck or cervical. In addition, the reference list of the McKenzie Institute website and the International Clinical Trials Registry Platform Search Portal were manually searched. Cross-referencing was undertaken through communications with experts in this field and relevant reviews. Inclusion criteria Etomidate are presented in Box 2. Two assessors (HT and RN) independently inspected studies to be included. Full text was inspected after exclusion of studies by screening the title and abstract. Disagreements were resolved by consensus. Design • Randomised controlled trials Participants • People with neck pain Intervention • Mechanical Diagnosis and Therapy (MDT) without other treatment modalities Outcome measures • Neck pain intensity Comparisons • MDT versus ‘wait and see’, act as usual, or placebo Methodological quality was assessed using the 10-point PEDro scale, excluding Item 1 (eligibility), as recommended because of its relevance to external not internal validity.

An increased ability to generate force in the major muscles of the lower limb may be important for adolescents with Down

syndrome, whose vocational roles may be influenced by their physical capacity. Although no corresponding changes in physical function were found, the observed SMDs for these variables (0.3 for the Grocery Shelving task and 0.5 for the timed stairs test) indicated a moderate observed effect size. Effect sizes of this magnitude are encouraging and are similar to those reported among adults with Down syndrome (Shields et DAPT order al 2008). If these SMD results were confirmed on a larger sample, then it is possible progressive resistance training might have clinically significant effects on the physical functioning of adolescents with Down syndrome. The SMDs for the physical functional measures were

smaller than for the muscle strength measures. This is expected as muscle strength is only one component required for these functional tasks; that is, there was less specificity of training for these functional tasks. Consistent with this, there are some data in people with Down syndrome to suggest that muscle strength is an important but not the only variable important in completing functional tasks (Cowley et al 2010). An innovative aspect of this trial was that the progressive resistance training intervention was led by physiotherapy student-mentors. This feature provided the supervision and the social interaction needed to encourage Antidiabetic Compound Library solubility dmso the adolescents to exercise. Choosing physiotherapy students to act as mentors was advantageous as they had an understanding of the principles of exercise training, and were also close in age to the adolescents so that the social interaction between the pair was meaningful. An additional benefit was that the

physiotherapy students had the opportunity to gain a unique experience of disability, something that they may not necessarily have gained from their professional training due to a lack of appropriate clinical placements. Progressive resistance training is a program typical of those that members of the community might undertake if they attended a community gym. The model developed and implemented in this study has the potential to become part of the on-going clinical experience ADAMTS5 of physiotherapy students and therefore could be an avenue for the long term sustainability of this type of community-based exercise program. It could also provide on-going opportunities for people with Down syndrome and those with other disabilities who require a high level of support to exercise. It is anticipated that, like with all novices, after a period of supervised exercise it may be possible for adolescents with Down syndrome to continue with the program with a lesser degree of supervision such as with a family member.

In summary, DNDI-VL-2098 is not extensively metabolized in preclinical species in vitro and in vivo, and in human microsomes and hepatocytes in vitro. To understand the disposition and excretion pathways of DNDI-VL-2098, studies with 14C labeled DNDI-VL-2098 are planned. DNDI-VL-2098 is a recently identified potent new oral lead compound for Visceral Leishmaniasis that is currently under preclinical development. Convenience of therapy (oral as opposed to parenteral treatment) and patient compliance are important goals for a successful new treatment for VL, particularly because it is endemic in rural areas. As such,

DNDI-VL-2098 represents a major breakthrough for an unmet medical need. The studies described here show that DNDI-VL-2098 possesses excellent preclinical in vitro and in vivo BMN 673 cost pharmacokinetic properties in a variety of rodent and non-rodent models. Allometric scaling of these data predicts that the compound will have good pharmacokinetics in humans and the predicted efficacious human doses are amenable to development. The in vitro microsomal intrinsic clearance of DNDI-VL-2098, and its in vivo clearance in animal

models showed a close relationship. PLX4032 manufacturer In vitro intrinsic clearance was very low in microsomes from all species (<0.6 mL/min/g liver), except in the hamster where it was moderately stable (2.5 mL/min/g liver) Rao et al., 2011. Similarly, the in vivo blood clearance was low in the mouse, rat and dog, and moderate in the hamster. In all of these cases, even if the blood clearance was assumed to entirely reflect only hepatic clearance, DNDI-VL-2098 would be predicted to have a low hepatic extraction ratio (0.10, 0.14 and 0.17 in mouse, rat and dog, respectively), and a moderate extraction ratio

of 0.4 in hamster. These data are consistent with generally good bioavailability of the compound in vivo. The results of the studies suggest that the efficacy of DNDI-VL-2098 seen in vivo in animal models crotamiton ( Gupta et al., 2013) results from the potency and pharmacokinetic profile of the parent compound, rather than on any active metabolites. Whether assessed in microsomes, or in hepatocytes, or in blood samples from in vivo dosed animals, DNDI-VL-2098 was metabolically stable and there was consistently no evidence for production of any meaningful metabolite based on LC–MS/MS–UV detection. The samples for in vivo biotransformation were taken following high oral doses leading to high blood concentration of parent drug. The time points selected for assessment (4–8 h post dose) adequately covered the parent compound half-life (1–6 h). Therefore, inadequate analytical sensitivity or early collection points appears unlikely to affect the ability to detect metabolites. Only one, very minor, mono-oxygenation metabolite was detectable in liver microsomes from preclinical species (less than 0.

Treatment of inflammation was initiated an hour after induction with croton oil and the reduction in oedema was measured after 3 h ( Fig. 1, left panel) and 6 h ( Fig. 1, right panel) with (R)-5 and (S)-5. After 3 h treatment, diclofenac inhibited oedema by 55.7 ± 8.4%. Compound (R)-5 was the least active (50.1 ± 4.2%), whilst compound (S)-5 and the racemate exhibited slightly higher activities (58.9 ± 4.0% and 60.0 ± 2.5% respectively). The difference in activity between (R)-5 and the racemate was significant

(P < 0.05). After 6 h treatment, the activity of diclofenac, (S)-5 buy Lumacaftor and the racemate decreased significantly, suggesting a relatively short duration of action. The difference in activity of (R)-5 between 3 and 6 h was the least significant (P > 0.05). After 6 h treatment, diclofenac was the least active (34.7 ± 7.2%; P < 0.001), followed by (S)-5 (39.0 ± 4.6%; P < 0.05), (R)-5 (40.1 ± 8.4%) and the racemate (42.4 ± 4.0%; P < 0.01). Cytotoxicity is an important factor to consider when testing for any biological activity. The in vitro cytotoxicity of the compounds were tested in mammalian RAD001 molecular weight cells and compared to diclofenac and

the known cytotoxic drug emetine. IC50 values are represented in Table 1. Diclofenac was the least toxic, followed by (R)-5, (S)-5 and the racemate. The racemate was approximately 10-fold more toxic than (S)-5, and approximately 20-fold more toxic than (R)-5. This difference in cytotoxicity profiles may indicate interactions with different receptor systems. In conclusion, (R)-5 which is naturally found does provide the best therapeutic option in terms of a favourable cytotoxicity profile. The varying anti-inflammatory activities and cytotoxicity profiles seem to suggest that (R)-5 and (S)-5 does

4-Aminobutyrate aminotransferase not share the same mechanism of action. All authors have none to declare. We acknowledge the University of KwaZulu-Natal Competitive Research Fund, NRF (Gun RH-6030732) and Rolexsi (Pty) Ltd for financial support. We also thank Ms Sithabile Buthelezi and Mr Dennis Ndwandwe for experimental assistance. “
“National Nanotechnology Initiative (NNI) define nanotechnology as the consumption of structures with at least one dimension of nanometer size for the production of materials, systems or devices with initially or extensively improved properties due to their nano size. Since nano-particles have high surface energy and a large surface area-to-volume ratio, it can provide high durability for fabrics, at the same time presenting good affinity for fabrics and enhance durability of the function. Nano-Tex known as a secondary of the US-based Burlington Industries have done the earliest work on nanotextiles.1 To apply nano-particles onto textiles, the most frequently used technique is coating. Textiles are generally composed of nano-particles; a surfactant, ingredients and a carrier medium to entrap the nano-particles.2 Spraying, transfer printing, washing, rinsing and padding are the several methods can apply coating onto fabrics.

Of the 100 randomized subjects (healthy infants) in cohort 2, 53 were females. The subjects were aged between 41 and 59 days with an average age of 47 days at the time of first dose. Treatment groups were comparable with regard to demography

and baseline characteristics (Table 1). The immune response was measured as the sero-response rates defined as the proportion of subjects with positive three-fold and four-fold sero-response (i.e. a threefold or more and four-fold or more rise in serum IgA anti-rotavirus antibody titres from baseline) after 28 days of administration of third dose for each treatment group. As per protocol analysis, the sero-response rates for placebo, BRV-TV dose-levels 105.0 FFU, 105.8 FFU, 106.4 find more FFU, and Rotateq at 28 days post third dose were 11.1%, 33.3%, 52.9%, 83.3%, and 68.4% respectively

using the three-fold or more criteria. The results showed statistically significant association for sero-response (p value = 0.0082) with the dose-levels (105.0, 105.8 or 106.4 FFU of each constituent serotype per 2.0 mL) of BRV-TV. A similar pattern of immune response was observed check details when sero-response rates using the four-fold or more rise of serum IgA anti-rotavirus antibody over baseline criteria were used (Fig. 1). The results showed a statistically significant association for sero-response (p value = 0.0022) between the dose-levels (105.0 FFU, 105.8 FFU or 106.4 FFU of each constituent serotype per 2.0 mL) of BRV-TV ( Fig. 2). By per protocol analysis, the GMC of serum IgA anti-rotavirus antibody titres at 28 days after the third dose was 8.4 U/mL in the placebo group, 13.3 U/mL in BRV-TV 105.0 group, 17.7 U/mL in BRV-TV 105.8 group, 57.7 U/mL in BRV-TV 106.4 group, and 48.4 U/mL in Rotateq group. whatever The GMC values corresponding to BRV-TV 106.4 FFU were higher than RotaTeq and Placebo following all three doses. An increase in the GMC values

was observed with increase in the antigen concentration level of the BRV-TV vaccine post all three doses, indicating a positive dose–response (Fig. 3). The proportion of subjects with positive polio antibody sero-response (titre value ≥8) after 28 days of administration of the third dose of trivalent oral polio vaccine were 97.8% for poliovirus type 1, 98.9% for poliovirus type 2 and 96.7% for poliovirus type 3. There was no difference in terms of reported sero-response against polio in all the five groups with polio antibody sero-response in the range of 94.4–100%. The stool samples were analysed post each dose of the vaccine/placebo. The frequency and duration of post-vaccination shedding of vaccine rotavirus in stool samples was determined by genotype (VP7 and VP4) analysis. One subject each in the group, BRV-TV 105.0 FFU, BRV-TV 106.4 FFU and placebo had rotavirus positive stools with the duration of shedding as 5, 3 and 7 days respectively. The rotavirus strains corresponding to group BRV-TV 105.0 FFU and BRV-TV 106.